Results per Page:
New clinical trials to target HER2 positive solid cancers
From Dr. Sara Hurvitz, Clinical Research Division, and colleagues
Anti-(idio)typical: a new immunogen to vaccinate against RSV
From the McGuire Lab, Vaccine & Infectious Disease Division
Going straight to the source in defense against infant RSV
New anti-idiotype antibody a first step in possible strategy to build infant immunity during vulnerable window
The past, present, and future of antibody-based pandemic protection
From the Bloom Lab, Basic Sciences Division
How studies of coronavirus immunity can inform better vaccines, treatments
Scientists look for broad-acting antibodies that could protect against new variants of SARS-CoV-2 — and maybe a future SARS-3
Taking aim: Mesothelin as a novel target for pediatric AML therapy
From the Meshinchi Lab, Clinical Research Division, and Cancer Consortium colleagues
Keep your enemies closer: targeting membrane-proximal domains for improved immunotherapy
From the Walter Lab, Clinical Research Division
Antibodies a hot topic in COVID-19 research
Hutch scientists tap their antibody expertise for new tests, treatments, vaccines
Mixing antibodies in silico: is more better?
From the Bloom Lab, Basic Sciences Division
Gimme shelter: CRISPR hides healthy cells from leukemia drug
In mouse study, gene-edited cells stay safe as immunotherapy attacks cancer
Double trouble: epithelial and B cell neutralization of Epstein-Barr virus
McGuire Laboratory, Vaccine and Infectious Disease Division